|
Alfaro R, Llorente S, Gonzalez-Martinez G, Jimenez-Coll V, Martinez-Banaclocha H, Galian JA, Botella C, Moya-Quiles MR, de la Pena-Moral J, Minguela A, Legaz I, Muro M. Clinical Significance of the Pre-Transplant CXCR3 and CCR6 Expression on T Cells In Kidney Graft Recipients. Transplant Proc. 2023 Jan-Feb;55(1):66-71. doi: 10.1016/j.transproceed.2022.12.012. Epub 2023 Jan 6. PubMed PMID: 36621349.
AÑO: 2023; IF: 0.8
|
36621349
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Banaclocha HM, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia. Clin Transl Oncol. 2023 May;25(5):1446-1454. doi: 10.1007/s12094-022-03042-z. Epub 2023 Jan 4. PubMed PMID: 36598635.
AÑO: 2023; IF: 2.8
|
|
Moya-Quiles MR, Muro M. Characterization of two new HLA class I alleles: HLA-B*35:572 and HLA-C*04:491. HLA. 2023 Jun;101(6):675-676. doi: 10.1111/tan.14966. Epub 2023 Jan 10. PubMed PMID: 36607232.
AÑO: 2023; IF: 5.9
|
|
Moya-Quiles MR, Muro M. Characterization of two new HLA-DPB1 alleles: HLA-DPB1*1443:01 and -DPB1*11:01:07. HLA. 2023 May;101(5):567-568. doi: 10.1111/tan.14945. Epub 2022 Dec 26. PubMed PMID: 36539968.
AÑO: 2023; IF: 5.9
|
|
Moya-Quiles MR, Muro M. Identification of three novel HLA class I alleles: HLA-A*02:1008, -A*24:553 and -C*12:350. HLA. 2023 Feb;101(2):145-146. doi: 10.1111/tan.14863. Epub 2022 Nov 1. PubMed PMID: 36274646.
AÑO: 2023; IF: 5.9
|